Start Codon cohort companies to receive One Nucleus membership benefits
CAMBRIDGE, UK, 11 December 2019 – Start Codon, a new model of life science and healthcare business accelerator, today announced it has partnered with One Nucleus, a membership organisation for life science and healthcare companies. Under the terms of the partnership agreement, One Nucleus will support and profile the life science and healthcare start-ups participating in the Start Codon accelerator programme.
Cambridge UK, 11 December 2019: Abcam has been honoured with a Glassdoor Employees’ Choice Award, recognising the Best Places to Work in 2020. Abcam is ranked 6th in Glassdoor’s Best Places to Work UK list.
The Employees’ Choice Awards are based solely on the input of employees who elect to provide feedback on their jobs, work environments and companies on Glassdoor, one of the world’s largest job and recruiting sites.
Events showcasing the latest products and innovations for lab professionals spans seven countries
Cambridge, UK, December 10 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has joined the EU-funded Exposome Project for Health and Occupational Research (EPHOR). The consortium aims to further elucidate the complex relationships between environment and disease by developing the concept of the ‘working-life exposome’, which takes into account all occupational and related non-occupational exposures (e.g. lifestyle) throughout the lifespan of an individual.
AMSBIO reports on the pioneering research published** by scientists at Stanford University Medical School that has cited Mimetix® aligned 3D cell culture scaffold supplied by the company to understand the architecture of the myelin sheaths which insulate neuronal axons, so they can transmit electrical impulses quickly and efficiently.
ScreenIn3D, a partner of AMSBIO, has been awarded the prestigious ELRIG Prize for Innovation in Drug Discovery at their flagship conference Drug Discovery 2019 which recently took place in Liverpool, UK.
Cambridge, UK and Moscow, Russia, 09 December 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has been informed that International Biotechnology Center (IBC) Generium, a leading Russian biopharmaceutical company, focused on developing and commercialising pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia (ALL).
Cambridge, UK, 09 December 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation technologies, today announced the addition of predesigned synthetic single guide RNA (sgRNA) to its product range. The sgRNAs, available individually or as library collections, expand the Company’s Edit-R gene engineering platform which provides a convenient and accessible approach to successful CRISPR gene editing.
Westbury, NY – Dec. 9, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a drug discovery webinar that will discuss how small interfering RNA (siRNA) molecules can be used to selectively suppress hepatic genes in an in vitro liver model and advance the development of small molecule and nucleic acid therapies.
Cambridge, UK - 9 December 2019 - Healx the AI-powered biotechnology company focused on developing breakthrough treatments for rare diseases, today announces it has entered into an agreement with Boehringer Ingelheim to identify indications related to rare neurological diseases.
The project will leverage Healx’s comprehensive AI-based drug discovery platform, Healnet, and expertise in rare diseases and pharmacology, to identify potential new indications for assets from Boehringer Ingelheim’s pipeline.